1d
Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report) yesterday and set a ...
In addition to trivalent inactivated influenza vaccines or trivalent recombinant influenza vaccine, the ACIP now recommends high-dose inactivated influenza vaccine (Fluzone High-Dose) or ...
The pandemic influenza vaccines business is even more unpredictable and depends almost exclusively on government stockpiling and supply contracts. A re-emerging focus for vaccine players ...
The combination candidate consists of Pfizer’s mRNA-based influenza vaccine candidate with the companies’ licensed COVID-19 vaccine. The Phase 3 trial measured two primary immunogenicity ...
At times, influenza A, like the A/Hong Kong/1/1968 ... Every year, various flu strains are chosen as vaccine candidates depending on surveillance data of the recent isolates and the performance ...
This week on Pipeline Moves, we kick off by looking at a Phase I/II trial completion by Moderna of its pandemic influenza vaccine off the back of a government grant. Meanwhile, an investigator-led ...
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program 12.09.2024 / 12:57 CET/CEST The issuer is solely responsible for the content of this announcement.
GSK plc announced positive headline results of a phase II trial (NCT06431607) for its mRNA seasonal influenza vaccine programme. The trial studied a range of mRNA formulations in older and younger ...
It is not inevitable that H5N1 will develop into a pandemic -- if we act now. Unfortunately, instead of urgent action, we ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback